Published Paper Details:

Abstract The prevalence of obesity has increased in recent years. Obesity can increase the risk of metabolic and cardiovascular disorders that are deadly. One of the metabolic diseases caused by obesity is type 2 diabetes mellitus. Type 2 diabetes mellitus or also known as non-insulin dependent type is a condition of insulin receptor resistance. Type 2 diabetes mellitus is caused by impaired insulin sensitivity, failure of pancreatic beta cells to maintain the amount of insulin to compensate for the resistance that occurs. The mechanism of insulin receptor resistance that commonly occurs is abnormalities of the insulin receptor that reduce INSR expression on the cell surface and post receptor abnormalities. The presence of a single-nucleotide in INSR. 4IBM affects the function of insulin receptors and increases the possibility of INSR-mediated diseases, one way to overcome this is by increasing the expression of 4IBM. Cinnamon (Cinnamomum verum) is a traditional plant that is often used as a medicinal ingredient for various disorders and based on previous research has been proven as a potential agent for managing diabetes mellitus. This research is an in silico study that aims to examine the potential of active chemicals contained in cinnamon and their role as 4IBM protein inhibitors for therapy in type 2 diabetes mellitus using Autodock tools 1.5.6 and based on the principle of Lamarckian genetic algorithm. Docking results showed binding energy ranged from -6.97 kcal/mol to -5.83 kcal/mol, with Epicathein compound having the smallest binding energy with an inhibitory constant of 7.74. This study can be used as a basis for conducting further research (in vivo and in vitro) related to the active chemicals of cinnamon and their effects as Diabetes Mellitus therapy.